Heartland Advisors’s TherapeuticsMD TXMD Stock Holding History

Heartland Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-6,000	Closed	-$1.58M	–	204
2017 Q2	$1.58M	Sell	6,000 -9,000	-60%	-$2.25M	0.1%	165
2017 Q1	$5.4M	Hold	15,000	–	–	0.33%	131
2016 Q4	$4.33M	Buy	15,000 +3,000	+25%	+$930K	0.24%	146
2016 Q3	$4.09M	Hold	12,000	–	–	0.23%	142
2016 Q2	$5.1M	Hold	12,000	–	–	0.29%	134
2016 Q1	$3.84M	Hold	12,000	–	–	0.2%	143
2015 Q4	$6.22M	Buy	12,000 +4,000	+50%	+$1.48M	0.25%	121
2015 Q3	$2.34M	Buy	+8,000	New	+$2.84M	0.09%	193

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Heartland Advisors's TXMD Position: Q3 2017 in Review

Heartland Advisors sold out of TherapeuticsMD (TXMD) in Q3 2017, closing a stake of 6,000 shares — an estimated $1.58M sold.

Heartland Advisors first reported a position in TXMD in Q3 2015 and held it in 8 quarters. The position peaked at $6.22M in Q4 2015. 134 funds tracked by Wall St. Rank hold TXMD as of Q3 2017.

Heartland Advisors reported no remaining TherapeuticsMD position as of Q3 2017 after selling out during the quarter.
Heartland Advisors sold 6,000 TherapeuticsMD shares in Q3 2017, an estimated $1.58M.
Heartland Advisors first reported a position in TherapeuticsMD in Q3 2015 and held it in 8 quarters.
Heartland Advisors's TherapeuticsMD position peaked at $6.22M in Q4 2015.
134 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2017.

Based on Heartland Advisors's 13F filing for Q3 2017, filed 25 Oct 2017.